Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood (2024) 144 (17): 1813–1820.

https://doi.org/10.1182/blood.2024025802

Published: 2024

Journal Articles

In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms

Angelo B. A. Laranjeira, Tim Kong, Steven C. Snyder, Mary C. Fulbright, Daniel A. C. Fisher, Daniel T. Starczynowski, Stephen T. Oh

Blood (2024) 143 (23): 2414–2424.

https://doi.org/10.1182/blood.2023022804

Published: 2024

Includes: Supplemental data

Journal Articles

Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL

Aaron T. Gerds, Ruben Mesa, John M. Burke, Michael R. Grunwald, Brady L. Stein, Peg Squier, Jingbo Yu, J. E. Hamer-Maansson, Stephen T. Oh

Blood (2024) 143 (16): 1646–1655.

https://doi.org/10.1182/blood.2023020232

Published: 2024

Includes: Supplemental data

Journal Articles

Aberrant Activity of the Calcium Sensor STIM1 Underlies Congenital Platelet Disorders and Myeloproliferative Neoplasms

Molly Brakhane, Vittorio Abbonante, Angelo B. A. Laranjeira, Christian Di Buduo, Brooke Sadler, Katrina Ashworth, Tim Kong, Fan He, Mary C. Fulbright, Dong Chen, Regina Clemens, Elena Pegoraro, Michele P. Lambert, Kandace Gollomp, Jorge Di Paola, Alessandra Balduini, Stephen T. Oh

Blood (2023) 142 (Supplement 1): 995.

https://doi.org/10.1182/blood-2023-186413

Published: 2023

Journal Articles

Leukemic Driver Clones Can Arise Independently and Outcompete MPN Cells in Post-MPN Secondary AML

Tyler M Parsons, Andrew L Young, Daniel A.C. Fisher, Maggie J Cox, Stephen T. Oh, Grant A Challen

Blood (2023) 142 (Supplement 1): 1784.

https://doi.org/10.1182/blood-2023-186610

Published: 2023

Journal Articles

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2023-187092

Published: 2023

Journal Articles

Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials

Ruben A. Mesa, Andrew C. Perkins, Yeow Tee Goh, Maria Laura Fox, Donal P McLornan, Jeanne Palmer, Lynda Foltz, Alessandro Maria Vannucchi, Steffen Koschmieder, Francesco Passamonti, Sung-Eun Lee, Jun Kawashima, Bryan Strouse, Francisco Gonzalez Carreras, Stephen T. Oh

Blood (2023) 142 (Supplement 1): 3182.

https://doi.org/10.1182/blood-2023-177774

Published: 2023

Journal Articles

In Vivo Ablation of NFκB Cascade Effectors Alleviates Disease Burden in Myeloproliferative Neoplasms

Angelo B. A. Laranjeira, Tim Kong, Steven Craig Snyder, Mary C. Fulbright, Daniel A.C. Fisher, Daniel T. Starczynowski, Stephen T. Oh

Blood (2023) 142 (Supplement 1): 991.

https://doi.org/10.1182/blood-2023-182290

Published: 2023

Journal Articles

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Blood (2023) 142 (Supplement 1): 628.

https://doi.org/10.1182/blood-2023-179141

Published: 2023

Journal Articles

Initial Results from Summit: An Ongoing, 3-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Prithviraj Bose, Stephen T. Oh, Brian Modena, Anthony M. Hunter, Cem Akin, Mariana Castells, Michael Manning, Richard Herrscher, Frank Siebenhaar, Daniel J. DeAngelo, Tracy I. George, Benjamin Exter, Jenna Zhang, Amanda Pilla, Hina Jolin, Rachael Easton, Lindsay A.M Rein

Blood (2023) 142 (Supplement 1): 77.

https://doi.org/10.1182/blood-2023-178927

Published: 2023

Journal Articles

Methods to Elucidate Hematopoietic Clonal Organization in Bone Marrow

Andrew L Young, Hannah C Davis, Maggie J Cox, Tyler M Parsons, Samantha C Burkart, Stephen T. Oh, Grant A Challen

Blood (2023) 142 (Supplement 1): 5595.

https://doi.org/10.1182/blood-2023-179367

Published: 2023

Journal Articles

Plasma Proteomic Signature Predicts Risk of Myeloid Neoplasm

J. Scott Beeler, Duc Tran, Jie Liu, Zilan Xin, Brian Wiley, Irenaeus C.C. Chan, Michael H. Kramer, Armel L. Batchi-Bouyou, Xiaoyu Zong, Matthew J. Walter, Sarantis Chlamydas, Francesca Ferraro, Stephen T. Oh, Ben Busby, Daniel C. Link, Yin Cao, Kelly L. Bolton

Blood (2023) 142 (Supplement 1): 940.

https://doi.org/10.1182/blood-2023-190857

Published: 2023

Journal Articles

RSK1 Is an Exploitable Dependency in Myeloid Malignancies

Tim Kong, Angelo B. A. Laranjeira, LaYow Yu, Jared Scott Fowles, Daniel A.C. Fisher, Sherwin Ng, Wei Yang, Fan He, Maggie J Cox, Mary C. Fulbright, Stacey L. Rentschler, My-my Huynh, Gerrit Los, Sandra E. Dunn, Grant A Challen, Stephen T. Oh

Blood (2023) 142 (Supplement 1): 46.

https://doi.org/10.1182/blood-2023-182320

Published: 2023

Journal Articles

Clinical and Disease Characteristics of Patients with Myelofibrosis and Essential Thrombocythemia Who Harbor a Calreticulin (CALR) Gene Mutation: Subanalysis of the MOST Study

Stephen T. Oh, Naveen Pemmaraju, Niyati Nathwani, Evan M. Braunstein, JE Hamer-Maansson, Tricia Kalafut, Ellen K. Ritchie

Blood (2023) 142 (Supplement 1): 3812.

https://doi.org/10.1182/blood-2023-179507

Published: 2023

Journal Articles

Retrospective Analysis of the Relationship between Transfusion Independence and Bone Marrow Fibrosis Reduction in Patients with Myelofibrosis Treated with Pacritinib Versus Ruxolitinib

Stephen T. Oh, Jamile Shammo, Vikas Gupta, Mary Frances McMullin, Prithviraj Bose, Ruben A. Mesa, Alessandro Lucchesi, Sarah Buckley, Purvi Suthar, Karisse Roman-Torres, John Mascarenhas, Francisca Ferrer Marin

Blood (2023) 142 (Supplement 1): 4566.

https://doi.org/10.1182/blood-2023-178753

Published: 2023

Journal Articles

Galectin-1 Fuels Monocyte-Driven Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms

Fan He, Tim Kong, Shuyang Lin, Mary C. Fulbright, Angelo B. A. Laranjeira, Daniel A.C. Fisher, Maggie J Cox, Katrina Ashworth, Jorge Di Paola, Stephen T. Oh

Blood (2023) 142 (Supplement 1): 4518.

https://doi.org/10.1182/blood-2023-189252

Published: 2023

Journal Articles

Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis

Stephen T Oh, Ruben Mesa, Claire Harrison, Prithviraj Bose, Aaron T. Gerds, Mark L. Heaney, Vikas Gupta, Bart L. Scott, Jean-Jacques Kiladjian, Alessandro Lucchesi, Sarah Buckley, Shanthakumar Tyavanagimatt, Karisse Roman-Torres, John Mascarenhas, Srdan Verstovsek

Blood (2022) 140 (Supplement 1): 1518–1521.

https://doi.org/10.1182/blood-2022-156936

Published: 2022

Journal Articles

Spatial Organization of Hematopoietic Clones in the Bone Marrow of a Patient with Polycythemia Vera

Andrew L Young, Hannah C Davis, David H Spencer, Timothy J Ley, Stephen T Oh, Matthew J Walter, Grant A Challen

Blood (2022) 140 (Supplement 1): 2910–2911.

https://doi.org/10.1182/blood-2022-167351

Published: 2022

Journal Articles

Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea (HU): A Longitudinal Analysis From REVEAL

Aaron T. Gerds, Michael R. Grunwald, Stephen T. Oh, Evan Braunstein, Zhenyi Xue, Valkal Bhatt, Jingbo Yu, Ruben Mesa

Blood (2022) 140 (Supplement 1): 6810–6812.

https://doi.org/10.1182/blood-2022-158144

Published: 2022

Journal Articles

Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum

Blood (2022) 140 (Supplement 1): 6803–6805.

https://doi.org/10.1182/blood-2022-162877

Published: 2022

NARROW

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms

Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL

Aberrant Activity of the Calcium Sensor STIM1 Underlies Congenital Platelet Disorders and Myeloproliferative Neoplasms

Leukemic Driver Clones Can Arise Independently and Outcompete MPN Cells in Post-MPN Secondary AML

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials

In Vivo Ablation of NFκB Cascade Effectors Alleviates Disease Burden in Myeloproliferative Neoplasms

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Initial Results from Summit: An Ongoing, 3-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Methods to Elucidate Hematopoietic Clonal Organization in Bone Marrow

Plasma Proteomic Signature Predicts Risk of Myeloid Neoplasm

RSK1 Is an Exploitable Dependency in Myeloid Malignancies

Clinical and Disease Characteristics of Patients with Myelofibrosis and Essential Thrombocythemia Who Harbor a Calreticulin (CALR) Gene Mutation: Subanalysis of the MOST Study

Retrospective Analysis of the Relationship between Transfusion Independence and Bone Marrow Fibrosis Reduction in Patients with Myelofibrosis Treated with Pacritinib Versus Ruxolitinib

Galectin-1 Fuels Monocyte-Driven Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms

Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis

Spatial Organization of Hematopoietic Clones in the Bone Marrow of a Patient with Polycythemia Vera

Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea (HU): A Longitudinal Analysis From REVEAL

Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only